Hai T. Tran

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Roy S. Herbst, Diane Prager, Róbert Hermann et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +13

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba et al. · Cancer Discovery · 2011 · 893 citations

Medicine, Oncology, Pharmacology +17

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 536 citations · Full text

Medicine, Oncology, Pharmacology +16